Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

The American Journal of Cardiology
Mazen HannaMathew S Maurer

Abstract

In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, tafamidis significantly reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is associated with a significant burden of disease; further analysis of patient-reported quality of life will provide additional data on the efficacy of tafamidis. In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, 441 adult patients with ATTR-CM were randomized (2:1:2) to tafamidis 80 mg, tafamidis 20 mg, or placebo for 30 months, with pooled tafamidis (80 mg and 20 mg) compared with placebo. Change in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) domain scores, EQ-5D-3L scores, and patient global assessment, were prespecified exploratory end points. A greater proportion of patients improved KCCQ-OS score at month 30 with tafamidis (41.8%) versus placebo (21.4%). Tafamidis significantly reduced the decline in all 4 KCCQ-OS domains (p <0.0001 for all), and in EQ-5D-3L utility (0.09 [confidence interval 0.05 to 0.12]; p <0.0001) and EQ visual analog scale (9.11 [confidence interval 5.39 to 12.83]; p <0.0001) scores at month 30 versus placebo. A larger proportion of...Continue Reading

References

Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Sep 28, 2005·Circulation·Rodney H Falk
Oct 8, 2005·American Heart Journal·John SpertusUNKNOWN Cardiovascular Outcomes Research Consortium
Feb 21, 2006·Journal of the American College of Cardiology·Paul A HeidenreichUNKNOWN Cardiovascular Outcomes Research Consortium
Sep 6, 2012·Circulation·Frederick L Ruberg, John L Berk
Nov 28, 2015·Journal of the American College of Cardiology·Morie A GertzGiampaolo Merlini
Jul 9, 2016·Journal of the American College of Cardiology·Mathew S MaurerUNKNOWN THAOS Investigators
Mar 23, 2017·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Jun 15, 2017·Circulation. Heart Failure·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
Aug 4, 2018·Neurology and Therapy·Michelle StewartWilliam R Lenderking
Aug 28, 2018·The New England Journal of Medicine·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
May 17, 2019·Muscle & Nerve·Aaron YarlasSpencer D Guthrie
May 22, 2019·Circulation·Thirusha LaneJulian D Gillmore
Jun 7, 2019·Journal of the American College of Cardiology·Frederick L RubergMathew S Maurer

❮ Previous
Next ❯

Citations

Jun 6, 2021·Cardiology and Therapy·Haruki KoikeMasahisa Katsuno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.